Adaptimmune Therapeutics PLC Form 3

January 04, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response... Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

Behbahani Ali

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

01/01/2016

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Adaptimmune Therapeutics PLC [ADAP]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

1954 GREENSPRING DRIVE, Â SUITE 600

(Street)

(Check all applicable) _X__ Director

Officer

10% Owner Other (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

TIMONIUM, MDÂ 21093

(City) (State) (Zip)

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership

Table I - Non-Derivative Securities Beneficially Owned

Form: Direct (D)

or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership

(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

4.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Title

(Instr. 4)

1. Title of Derivative Security 2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

Price of Derivative Security

5. Conversion Ownership or Exercise Form of Derivative Security:

6. Nature of Indirect Beneficial Ownership

(Instr. 5)

Date Exercisable Expiration Date

Amount or Number of Shares

Direct (D) or Indirect

(I)

(Instr. 5)

Option to purchase Ordinary Shares 05/11/2015 05/11/2025 Ordinary Shares 155,682 \$ 2.8379 D Â

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Behbahani Ali
1954 GREENSPRING DRIVE SUITE 600
TIMONIUM, MDÂ 21093

Signatures

**Signature of Reporting Person

/s/ Sasha Keough, attorney-in-fact 01/04/2016

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The exercise price was converted from 1.82 pounds sterling based on the noon buying rate of the Federal Reserve Bank of New York for (1) the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2